Co-Diovan

Co-Diovan is a combination antihypertensive medicine containing two active ingredients - valsartan, an angiotensin II receptor blocker (ARB), and hydrochlorothiazide (HCTZ), a thiazide diuretic. It is used in the treatment of essential hypertension (raised blood pressure with no identifiable secondary cause) in adults whose blood pressure is not adequately controlled by either agent alone. The combination offers complementary and synergistic mechanisms, often achieving better blood pressure control than either drug at higher doses used as monotherapy.

Available Strengths

Co-Diovan is available in several fixed-dose combination strengths to allow flexible prescribing: 80 mg/12.5 mg, 160 mg/12.5 mg, 160 mg/25 mg, and 320 mg/25 mg tablets (valsartan/hydrochlorothiazide). This range allows the prescriber to optimise treatment according to the individual patient's response and tolerability. Patients may be initiated on a lower-strength combination and uptitrated over several weeks to achieve the target blood pressure.

Mechanism of Blood Pressure Lowering

The two components work through complementary mechanisms. Valsartan blocks the action of angiotensin II at the AT1 receptor, preventing the vasoconstriction and aldosterone release that angiotensin II would otherwise promote. This results in vasodilation and reduced sodium and water retention. Hydrochlorothiazide acts on the distal convoluted tubule of the kidney to inhibit sodium and chloride reabsorption, promoting diuresis and thereby reducing plasma volume. The volume depletion caused by the diuretic tends to activate the renin-angiotensin system, which would partially counteract the diuretic effect - but this activation is then blocked by valsartan, explaining the synergy between the two components.

Teratogenicity Warning

Co-Diovan is absolutely contraindicated in pregnancy. Valsartan and other ARBs, like ACE inhibitors, are teratogenic and fetotoxic. Use during the second and third trimesters can cause renal failure, oligohydramnios (reduced amniotic fluid), skull defects, limb contractures, and death in the foetus. Women of childbearing potential must use effective contraception while taking this medicine and must discontinue it immediately if pregnancy is suspected or confirmed.

How to Take Co-Diovan

Co-Diovan tablets are taken once daily, with or without food, at approximately the same time each day. Swallow the tablet whole with a glass of water. Because the hydrochlorothiazide component has a diuretic effect that increases urine output, take your tablet in the morning rather than in the evening to avoid disrupting your sleep with overnight toilet trips.

Blood pressure medicines generally work best when taken consistently every day, even when you feel well. Do not stop Co-Diovan without speaking to your doctor — blood pressure can rise quickly after stopping.

Staying Hydrated

Maintain good fluid intake, especially in hot weather, during illness with vomiting or diarrhoea, or during intense exercise. The diuretic component can deplete fluid and electrolytes more quickly in these situations, leading to dizziness or dehydration. Let your doctor know if you feel persistently dizzy or excessively thirsty.

Co-Diovan is available in fixed-dose combinations and the appropriate strength is selected by the prescriber based on the patient's current blood pressure, prior treatment, and response.

Initial combination therapy: Patients new to combination antihypertensive treatment are often started on Co-Diovan 80/12.5 mg or 160/12.5 mg once daily.

Uptitration: If blood pressure remains inadequately controlled after 2 to 4 weeks, the dose can be increased to 160/25 mg or 320/25 mg once daily.

Maximum dose: Co-Diovan 320/25 mg once daily represents the maximum recommended dose.

Renal impairment: Caution is required in patients with moderate renal impairment (eGFR 30-60 mL/min/1.73m2). Co-Diovan is contraindicated in severe renal impairment (eGFR below 30 mL/min/1.73m2).

Hepatic impairment: Caution in mild to moderate hepatic impairment; contraindicated in severe hepatic impairment, biliary cirrhosis, or cholestasis.

Elderly: No routine dose adjustment required, but elderly patients should be monitored for hypotension and electrolyte disturbances.

Common Side Effects

• Dizziness or light-headedness, especially on standing up quickly (postural hypotension)
• Headache
• Fatigue
• Nausea or stomach discomfort
• Nasopharyngitis (cold-like symptoms)
• Raised blood potassium levels (with the valsartan component)

Important Warnings

Do not take Co-Diovan if you are pregnant or trying to conceive. Valsartan (an angiotensin receptor blocker) and other medicines acting on the renin-angiotensin system can seriously harm a developing baby and must be stopped before pregnancy. If you become pregnant while taking Co-Diovan, tell your doctor immediately. Kidney function and electrolyte levels should be monitored periodically, particularly if you are also taking other blood pressure medicines or NSAIDs.

Electrolyte Monitoring and Renal Function

The combination of an ARB and a diuretic in Co-Diovan necessitates regular monitoring of renal function, serum electrolytes (particularly sodium and potassium), and blood pressure, especially at the start of treatment and after dose adjustments. Hypokalaemia (low potassium) from HCTZ and hyperkalaemia (high potassium) from valsartan may both occur depending on individual patient factors, so a balanced electrolyte picture should not be assumed. Patients with pre-existing renal impairment, heart failure, or diabetes are at higher risk of significant electrolyte disturbances and acute kidney injury and require closer monitoring.

Teratogenicity and Contraception

Co-Diovan must not be used in pregnancy. ARBs and ACE inhibitors (the "sartans" and "-prils") are teratogenic, causing serious harm to the developing foetus including renal failure, skull hypoplasia, and death. Women of childbearing potential must use reliable contraception while taking Co-Diovan. If pregnancy is discovered or planned, Co-Diovan must be discontinued immediately and replaced with a pregnancy-safe antihypertensive such as labetalol, methyldopa, or nifedipine, under medical supervision. Long-term treatment with HCTZ has also been associated with a small increase in the risk of non-melanoma skin cancer, so patients should be advised to use sun protection.

Co-Diovan is contraindicated in the following situations:

• Known hypersensitivity to valsartan, hydrochlorothiazide, sulphonamide-derived drugs, or any excipient
• Pregnancy (all trimesters) - teratogenic and fetotoxic
• Breastfeeding
• Severe hepatic impairment, biliary cirrhosis, or cholestasis
• Severe renal impairment (eGFR below 30 mL/min/1.73m2) or anuria
• Concurrent use with aliskiren (direct renin inhibitor) in patients with diabetes or renal impairment
• Concurrent use with ACE inhibitors due to increased risk of hypotension, hyperkalaemia, and renal impairment
• Refractory hypokalaemia, hypercalcaemia, or symptomatic hyperuricaemia (gout)
• History of angioedema related to prior ARB or ACE inhibitor therapy